Bayer Presents New Study Results for Xarelto

Data : 30/03/2020 @ 08:54
Fonte : Dow Jones News
Titolo : Bayer AG (BAYN)
Quotazione : 63.94  3.22 (5.30%) @ 17:35
Quotazione Bayer Grafico

Bayer Presents New Study Results for Xarelto

Grafico Azioni Bayer (XE:BAYN)
Storico


Da Mar 2020 a Giu 2020

Clicca qui per i Grafici di Bayer

By Kim Richters

 

Bayer AG over the weekend presented two new studies and results for its blood thinner Xarelto.

The German pharmaceutical and chemical company said the drug plus aspirin reduces the combined risk of limb ischemia and major cardiovascular events for patients who have a symptomatic peripheral artery disease after revascularization.

The results are from the Phase 3 VOYAGER PAD study, the company said.

Another study showed that Xarelto lowers the risk of major venous thromboembolism after minor orthopaedic surgery, Bayer said.

This data is from the from the clinical Phase 3 trial PRONOMOS, it said.

 

Write to Kim Richters at kim.richters@wsj.com

 

(END) Dow Jones Newswires

March 30, 2020 02:39 ET (06:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
La tua Cronologia
BIT
BMPS
Monte Pasc..
BITI
FTSEMIB
FTSE Mib
BIT
UCG
Unicredit
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs Do..
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.

Registrati ora per creare la tua watchlist personalizzata in tempo reale streaming.

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

P: V:it D:20200603 01:08:08